RecruitingPhase 3NCT06631287

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC)

Sponsor

Wes Ely

Enrollment

550 participants

Start Date

Oct 21, 2024

Study Type

INTERVENTIONAL

Conditions

SARS-CoV-2 infection COVID-19 Long COVID Coronavirus Infections

Summary

The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Baricitinib and Placebo for people with covid-19, coronavirus infections, and other related conditions. The study is currently recruiting participants at 17 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBaricitinib

4mg encapsulated, pre-formed tablet PO once daily for 24 weeks.

OTHERPlacebo

Matched placebo capsule, PO once daily for 24 weeks.

Locations(17)

University of Arizona

Tucson, Arizona, United States

University of California, Los Angeles (UCLA)

Los Angeles, California, United States

University of California San Francisco

San Francisco, California, United States

University of Colorado I Anschutz Medical Campus

Aurora, Colorado, United States

Yale University

New Haven, Connecticut, United States

University of Florida College of Medicine

Gainesville, Florida, United States

Emory University

Atlanta, Georgia, United States

Illinois Research Network (ILLInet), University of Illinois Chicago

Chicago, Illinois, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

University of Minnesota

Minneapolis, Minnesota, United States

NYU Langone Health - Brooklyn

Brooklyn, New York, United States

University Hospitals Cleveland Case Western

Cleveland, Ohio, United States

The MetroHealth System

Cleveland, Ohio, United States

Vanderbilt University Medical

Nashville, Tennessee, United States

University of Texas at San Antonio

San Antonio, Texas, United States

Swedish Medical Center

Seattle, Washington, United States

West Virginia Clinical and Translational Science Institute

Morgantown, West Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06631287

Related Trials

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

NCT075363086 locations

Viral Infections in Healthy and Immunocompromised Hosts

NCT013060841 location

Longitudinal Population-based Observational Study of COVID-19 in the UK Population

NCT043305991 location

Heat thErapy And mobiLity in COVID-19 Survivors

NCT069281161 location

Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation

NCT069406091 location